ArticleGastroenterology and hepatology from bed to bench2012
The relation between the level of interleukin-23 with duration and severity of ulcerative colitis.
Article in Gastroenterology and hepatology from bed to bench, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Systemic Cytokine Patterns and Histologic Disease Spectrum in Inflammatory Bowel Disease.Current issues in molecular biology · 2026Article
- Systemic Immune Signatures of Endoscopic-Histologic Discordance in Inflammatory Bowel Disease: A Pilot Study.Journal of clinical medicine · 2026Article
- Serum Interleukin-10 as a Potential Biomarker for Deep Remission and Histologic Activity in Ulcerative Colitis.Biomedicines · 2026Article
- Interleukin Signatures as Prognostic Biomarkers in Ulcerative Colitis: From Immune Pathways to Clinical Prediction.Current issues in molecular biology · 2026Review
- Interleukin-23 in lung and airway diseases: from pathogenesis to precision-guided therapeutic targeting.Frontiers in pharmacology · 2026Review
- A scalable human gut-immune co-culture model for evaluating inflammatory bowel disease anti-inflammatory therapies.SLAS discovery : advancing life sciences R & D · 2025Article
- The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease.International journal of molecular sciences · 2023Review
- Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease.International journal of molecular sciences · 2022Review
- The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases.Current issues in molecular biology · 2022Review
- The regulatory mechanism and potential application of IL-23 in autoimmune diseases.Frontiers in pharmacology · 2022Review
- Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease.Journal of personalized medicine · 2021Article
- Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights.Bioprocess and biosystems engineering · 2021Review
- The Effects of the Marine-Derived Polysaccharides Laminarin and Chitosan on Aspects of Colonic Health in Pigs Challenged with Dextran Sodium Sulphate.Marine drugs · 2020Article
- Interleukin 23 and autoimmune diseases: current and possible future therapies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- The Expanding Role of Anti-IL-12 and/or Anti-IL-23 Antibodies in the Treatment of Inflammatory Bowel Disease.Gastroenterology & hepatology · 2019Article
- Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection.Digestive diseases and sciences · 2018Observational
- Serum Cytokine Profile in Asian Indian Patients with Takayasu Arteritis and its Association with Disease Activity.The open rheumatology journal · 2017Article
- IL23 as a novel serum based biomarker in ulcerative colitis- an editorial.Gastroenterology and hepatology from bed to bench · 2012Article
- Interleukin Signatures as Histology-Aligned Biomarkers in Inflammatory Bowel Disease.Inflammatory intestinal diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn this study, we determined the relationship between the serum level of IL-23 and the severity of ulcerative colitis (UC) among our population.
backgroundA recent major breakthrough for describing the pathogenesis of intestinal tissue injury in inflammatory bowel disease (IBD) is the pathway related to interleukin-23 (IL-23). PATIENTS AND
methodsWe performed a prospective case-control study on a total of 85 new patients with ulcerative colitis, recruited from a general referral hospital. Forty ethnically matched healthy controls were also enrolled among hospital staffs and analyzed. Serum IL-23 level was quantified using an electrochemiluminescence immunoassay (ECLIA) method with an immunoassay analyzer.
resultsThe mean serum IL-23 level in the group with ulcerative colitis was significantly higher than the healthy individuals (347.5±130.8 pg/ml versus 233.5±86.3 pg/ml; p< 0.001). There was a positive correlation between the serum level of IL-23 and disease duration (r = 0.27, p = 0.04). Also, a direct relationship was found between the serum level of IL-23 and the severity of disease (mean IL-23 in mild UC = 296.2±51.2 pg/ml; in moderate UC= 356.1±142.9 pg/ml; and in severe UC= 399.3±163.8 pg/ml, p = 0.04).
conclusionSerum level of IL-23 is directly correlated with the duration and severity of ulcerative colitis.
Indexed as
Identifiers
24834198PMC4017442W2134836777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.